JACC: CardioOncology - Prognosis after Withdrawal of Cardioprotective Therapy in Patients with Improved Cancer Therapeutics-Related Cardiac Dysfunction

In this episode, Brian Halliday discusses a Korean study examining the outcomes of patients with cancer therapeutics-related cardiac dysfunction after withdrawing cardioprotective therapy. He highlights that while patients with an ejection fraction between 45 and 55% fared similarly regardless of therapy continuation, those with an ejection fraction below 45% experienced worse outcomes when they withdrew treatment, underscoring the need for further randomized trials to refine therapeutic approaches.